A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-typeKRASwho have received first-line systemic therapy

Metastatic Colon Cancer, Version 3.2013

(2017) Al B. Benson et al.   Journal of the National Comprehensive Cancer Network

FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study

(2015) Nicola Personeni et al.   Clinical Colorectal Cancer

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).

(2015) Paul Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2015) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma

(2015) Karthiga Santhana Kumar et al.   SpringerPlus

The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis

(2014) Christina Therkildsen et al.   ACTA ONCOLOGICA

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

(2014) J. Y. Douillard et al.   ANNALS OF ONCOLOGY

Characterization of rare transformingKRASmutations in sporadic colorectal cancer

(2014) Joanna HM Tong et al.   CANCER BIOLOGY & THERAPY

MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors

(2014) Paolo Luraghi et al.   CANCER RESEARCH

KRAS insertions in colorectal cancer: What do we know about unusual KRAS mutations?

(2014) Mariana Petaccia de Macedo et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Cetuximab-Induced MET Activation Acts as a Novel Resistance Mechanism in Colon Cancer Cells

(2014) Na Song et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter-Mediated Drug Resistance

(2014) A. Aoyama et al.   MOLECULAR CANCER THERAPEUTICS

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma

(2014) Rajani Kanteti et al.   PLoS One

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

(2013) R. Katayama et al.   CANCER RESEARCH

The emerging role of MET/HGF inhibitors in oncology

(2013) Giorgio V. Scagliotti et al.   CANCER TREATMENT REVIEWS

Role of cMET in the Development and Progression of Colorectal Cancer

(2013) Juan Pérez-Vargas et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

(2013) Yoon-Koo Kang et al.   INVESTIGATIONAL NEW DRUGS

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

(2013) Darren R. Feldman et al.   INVESTIGATIONAL NEW DRUGS

The quest to overcome resistance to EGFR-targeted therapies in cancer

(2013) Curtis R Chong et al.   NATURE MEDICINE

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK

(2013) Yong-Liang Yao et al.   PLoS One

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

(2013) Deniz Tural et al.   TUMOR BIOLOGY

Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

(2013) Alberto Bardelli et al.   Cancer Discovery

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

(2012) Jonathan W. Goldman et al.   CANCER

Tivantinib in hepatocellular carcinoma

(2012) Jörg Trojan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk

(2012) Alexandros Garouniatis et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer

(2012) Alexandra Voutsina et al.   MODERN PATHOLOGY

Is There a Role for IGF1R and c-MET Pathways in Resistance to Cetuximab in Metastatic Colorectal Cancer?

(2011) Alessandro Inno et al.   Clinical Colorectal Cancer

Diosgenin Suppresses Hepatocyte Growth Factor (HGF)-Induced Epithelial–Mesenchymal Transition by Down-regulation of Mdm2 and Vimentin

(2011) Hsiang-Yu Chang et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

(2011) A. A. Adjei et al.   ONCOLOGIST

HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation

(2010) D. Liska et al.   CLINICAL CANCER RESEARCH

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

(2009) Fotios Loupakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy

(2009) David Z Chang et al.   Journal of Hematology & Oncology

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil

(2008) P. Pfeiffer et al.   ANNALS OF ONCOLOGY

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

(2008) Zhao-Shi Zeng et al.   CANCER LETTERS

KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

(2008) Astrid Lièvre et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE